Vaxart Gets $9M BARDA Award for Phase 2b of COVID-19 Oral Pill Vaccine

 - 10,000-subject Phase 2b study would evaluate Vaxart’s next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator -

- Project NextGen is a $5 billion initiative by the U.S. Department of Health and Human Services to develop innovative vaccines and therapeutics providing broader and more durable protection for COVID-19 -

https://www.globenewswire.com/news-release/2024/01/19/2812305/25416/en/Vaxart-Receives-9-27-Million-BARDA-Project-NextGen-Award-to-Prepare-for-Phase-2b-Clinical-Study-Evaluating-Its-COVID-19-Oral-Pill-Vaccine-Candidate.html